摘要
背景人参皂甙 Rg3，从人参孤立的主要部件，禁止某些瘤生长和 angiogenesis。低剂量化疗和 antiangiogenesis 禁止者的联合比常规治疗更有效地压制试验性的瘤的生长。卵巢的癌症上的这联合的效果尚待被评估。因此，我们在人的卵巢的 cancer.Methods 的生长和 angiogenesis 上调查了人参皂甙 Rg3 和 cyclophosphamide (CTX ) 的协同 28 只女 athymic 老鼠随机被划分成 4 组 7：人参皂甙 Rg3， CTX，人参皂甙 Rg3 和 CTX 联合和控制，在与卵巢的癌症房间(SKOV-3 ) 被移植以后。老鼠为 SKOV-3cells 的 10 天后面的接种被给人参皂甙 Rg3 和 CTX 的 intraperitoneal 注射。老鼠的生活天的生活质量和数字被记录。瘤的尺寸，瘤禁止的率，生活延伸率，增殖的房间原子抗原标记索引( PCNALI )，脉管的 endothelial 房间生长因素( VEGF )和瘤纸巾的 microvessel 密度( MVD )的表示是在人参皂甙的鼠标的 estimated.Results 生活质量 Rg3 和联合治疗组更好并且比控制长生活天数。每个对待的组的平均的瘤重量是不到控制，在对待的组之中没有重要差别。对待的组的 PCNALI 比控制低。在对待的组的 MVD 价值和 VEGF 表示比控制显著地低， MVD 人参皂甙 Rg3 和联合治疗组珍视显著地比 CTX group.Conclusions 人参皂甙 Rg3 的低当独自使用了或与 CTX 结合了时，禁止了卵巢的癌症的生长和 angiogenesis。人参皂甙 Rg3 和 CTX 联合互相增强了 antitumour 效果并且与瘤改进了生活质量和老鼠的幸存时间。
Background Ginsenoside Rg3, the main component isolated from ginseng, inhibits some kinds of tumour growth and angiogenesis. The combination of low dose chemotherapy and antiangiogenesis inhibitors suppresses growth of experimental tumours more effectively than conventional therapy. The effect of this combination on ovarian cancer remains to be evaluated. Therefore, we investigated the synergism of ginsenoside Rg3 and cyclophosphamide （CTX） on growth and angiogenesis of human ovarian cancer.
Methods Twenty-eight female athymic mice were divided randomly into 4 groups of 7： ginsenoside Rg3, CTX, ginsenoside Rg3 and CTX combination and control, after being transplanted with ovarian cancer cells （SKOV-3）. The mice were given intraperitoneal injection of ginsenoside Rg3 and CTX for the 10 days following inoculation of SKOV-3 cells. The life quality and number of living days of mice were recorded. The size of tumour, tumour inhibitive rate, life elongation rate, proliferating cell nuclear antigen labelling index （PCNALI）, expression of vascular endothelial cell growth factor （VEGF） and microvessel density （MVD） of the tumour tissues were estimated.
Results Life quality of mice in ginsenoside Rg3 and combined treatment groups were better and number of living days longer than control. Average tumour weights of each treated group were less than control and there was no significant difference among the treated groups. PCNALI of treated groups was lower than control. The MVD value and VEGF expression in treated groups were significantly lower than control and the MVD values of ginsenoside Rg3 and combined treatment groups were lower than that of CTX group.
Conclusions Ginsenoside Rg3 significantly inhibited growth and angiogenesis of ovarian cancer when used alone or combined with CTX. Ginsenoside Rg3 and CTX combination reinforced the antitumour effect each other and improved the living quality and survival time of mice with tumour.
